Disintegration and esophageal irritation profiles of alendronate formulations: implications for clinical safety and efficacy.
Background: Fosamax (alendronate sodium, Merck & Co., Inc., Whitehouse Station, NJ, USA) is an effective oral bisphosphonate widely used to treat and prevent osteoporosis, with a safety and tolerability profile similar to placebo in clinical trials. It has been evaluated in clinical trials with over...
| Publicado en: | Journal of Applied Research Vol. 5; no. 2; pp. 253 - 266 |
|---|---|
| Autores principales: | , , , , , , , , , , , , |
| Formato: | pictorial research tables/charts Journal Article |
| Publicado: |
Therapeutic Solutions LLC
2005
|
| Acceso en línea: | Ver este registro en EBSCOhost |